Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Phenotypic and functional abnormalities of T lymphocytes in pathological hyperprolactinemia


The phenotype and function of T cells circulating in patients with pathological hyperprolactinemia were analyzed and compared to those in sex- and age-matched control subjects. Two-color immunofluorescence study revealed an increased number of CD4+ TQ1+ cells and the presence of phenotypically immature CD1+ T cells, also exhibiting transferrin surface receptor, in peripheral blood of the hyperprolactinemic patients. After chronic treatment with the dopamine agonist bromocriptine, T-cell abnormalities disappeared. In addition, some untreated patients showed enhanced T-cell suppressor activity in anin vitro pokeweed mitogen-driven B-cell transformation assay. These immunological findings confirm a link between neuroendocrine and immune systems in humans.

This is a preview of subscription content, log in to check access.


  1. 1.

    Blalock JE: The immune system as sensory organ. J Immunol 132:1067, 1984

  2. 2.

    Hall NR, Goldstein AL: The thymus-brain connection: Interactions between thymosin and the neuroendocrine system. Lymphokine Res 2:1, 1983

  3. 3.

    Comsa J, Leonhardt H, Ozminski K: Hormonal influences on the secretion of the thymus. Thymus 1:81, 1979

  4. 4.

    Nagy E, Friesen HG, Sehon AH, Berczi I: Immunomodulation in rats by transplantable anterior pituitary tumors. Endocrinology 116:1117, 1985

  5. 5.

    Kiess W, Butenandt O: Specific growth hormone receptors on human peripheral mononuclear cells: Reexpression, identification and characterization. J Clin Endocrinol Metab 60:740, 1985

  6. 6.

    Mercola KE, Cline MJ, Golde DW: Growth hormone stimulation of normal and leukemic human T-lymphocyte proliferation in vitro. Blood 58:337, 1981

  7. 7.

    Russel DH, Kibler R, Matrisian L, Larson DF, Poulos B, Magun BE: Prolactin receptors on human T and B lymphocytes: Antagonism of prolactin binding by cyclosporine. J Immunol 134:3027, 1985

  8. 8.

    Russel DH, Buckley AR, Montgomery DW, Larson NA, Gout PW, Beer CT, Putnam CW, Zukoski CF, Kibler R: prolactin-dependent mitogenesis in NB 2 node lymphoma cells: Effects of immunosuppressive cyclopeptides. J Immunol 138:276, 1987

  9. 9.

    Nagy E, Berzi I, Friesen HG: Regulation of immunity in rats by lactogenic and growth hormones. Acta Endocrinol 102:351, 1983

  10. 10.

    Vidaller A, Llorente L, Larrea F, Mendez JP, Alcocervarela J, Alarcon-Segovia D: T-cell dysregulation in patients with hyperprolactinemia: Effect of bromocriptine treatment. Clin Immunol Immunophatol 38:337, 1986

  11. 11.

    Gerli R, Rambotti P, Nicoletti I, Orlandi S, Migliorati G, Riccardi C: Reduced number of natural killer cells in patients with pathological hyperprolactinemia. Clin Exp Immunol 64:399, 1986

  12. 12.

    Thorner MO, Fluckiger E, Calne DB (eds): Bromocriptine. A Clinical and Pharmacological Review. New York, Raven Press, 1980

  13. 13.

    Nicoletti I, Filipponi P, Fedeli L, Palumbo R, Santori P, Santeusanio F, Brunetti P: Progesterone positive feedback on gonadotropin release in estrogen-primed postmenopausal women: Central nervous system and pituitary as possible sites of action. J Clin Endocrinol Metab 53:135, 1981

  14. 14.

    Velardi A, Rambotti P, Cernetti C, Spinozzi F, Gerli R, Martelli MF, Davis S: Monoclonal antibody-defined T-cell phenotypes and phytohemagglutinin reactivity of E-rosetteforming circulating lymphocytes from untreated chronic myelocytic leukemia patients. Cancer 53:913, 1984

  15. 15.

    Reinherz EL, Schlossman SF: Regulation of the immune response. Inducer and suppressor T-lymphocyte subsets in human beings. N Engl J Med 303:370, 1980

  16. 16.

    Stashenko P, Nadler LM, Hardy R, Schlossman SF: Characterization of a human B lymphocyte-specific antigen. J Immunol 125:1678, 1980

  17. 17.

    Corte G, Mingari MC, Moretta A, Bargellesi A: Human T cell subpopulations defined by a monoclonal antibody. I. A small subset is responsible for proliferation to allogenic cells or to soluble antigens and for helper activity for B-cell differentiation. J Immunol 128:16, 1982

  18. 18.

    Ledbetter JA, Evans RL, Lipinski M, Cunningham-Rundles C, Good RA, Herzenberg LA: Evolutionary conservation of surface molecules that distinguish T lymphocyte helper/inducer and T cytotoxic/suppressor subpopulations in mouse and man. J Exp Med 153:310, 1981

  19. 19.

    Reinherz EL, Morimoto C, Fitzgerald KA, Hussey RE, Daley JF, Schlossman SF: Heterogeneity of human CD4+ inducer T cells defined by a monoclonal antibody that delineates two functional subpopulations. J Immunol 128:463, 1982

  20. 20.

    Gerli R, Rambotti P: Characterization of immature T cell subpopulations in neonatal blood. Blood 65:508, 1985

  21. 21.

    Gerli R, Rambotti P, Cernetti C, Velardi A, Spinozzi F: Evidence for phenotypic T-precursor cells in human cord blood. Br J Haematol 53:685, 1983

  22. 22.

    Sutherland R, Delia D, Schneider C, Newman R, Kemshead J, Greaves MF: Ubiquitous cell surface glycoprotein on tumor cells is proliferation-associated receptor transferrin. Proc Natl Acad Sci USA 78:4515, 1981

  23. 23.

    Stingl G: Role of epidermal Langerhans cells in the immune response.In Recent Advances in Clinical Immunology, RA Thompson, NR Rose (eds). Edinburgh, Churchill Livingstone, 1983, Vol III, p 1

  24. 24.

    Andersson U, Britton S, De Ley M, Bird G: Evidence for the ontogenic precedence of suppressor T cell functions in the human neonate. Eur J Immunol 13:6, 1983

  25. 25.

    Gerli R, Bertotto A, Spinozzi F, Cernetti C, Grignani F, Rambotti P: Phenotypic dissection of cord blood immunoregulatory T-cell subsets by using a two color immunofluorescence study. Clin Immunol Immunopathol 40:429, 1986

  26. 26.

    Gerli R, Rambotti P, Cernetti C, Velardi A, Spinozzi F, Tabilio A, Martelli MF, Grignani F, Davis S: A mature thymocyte-like phenotypic pattern on human cord circulating T-lymphoid cells. J Clin Immunol 4:461, 1984

  27. 27.

    Fine SA, Frohman LA: Loss of central nervous system component dopaminergic inhibition of prolactin secretion in patients with prolactin-secreting pituitary tumors. J Clin Invest 61:973, 1978

  28. 28.

    Nicoletti I, Filipponi P, Fedeli L, Sfrappini M, Gregorini G, Ambrosi F, Santeusanio F: Catecholamines and pituitary function. III. Restoration of the prolactin response to thyrotropin-releasing hormone by low-dose dopamine infusion in women with pathological hyperprolactinemia. Hormone Res 20:202, 1984

  29. 29.

    Riccardi C, Santoni A, Barlozzari T, Herberman RB: In vivo reactivity of mouse natural killer (NK) cells against normal bone marrow cells. Cell Immunol 60:136, 1981

  30. 30.

    Hansson M, Kiessling R, Andersson B, Karre K, Roder J: NK cell-sensitive T-cell subpopulation in thymus: Inverse correlation to host NK activity. Nature 278:174, 1979

  31. 31.

    Hiestand PC, Mekler P, Nordmann R, Grieder A, Permmongkol C: Prolactin as a modulator of lymphocyte responsiveness provides a possible mechanism of action of cyclosporine. Proc Natl Acad Sci USA 83:2599, 1986

Download references

Author information

Correspondence to P. Rambotti.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Gerli, R., Riccardi, C., Nicoletti, I. et al. Phenotypic and functional abnormalities of T lymphocytes in pathological hyperprolactinemia. J Clin Immunol 7, 463–470 (1987).

Download citation

Key words

  • Pathological hyperprolactinemia
  • T lymphocytes
  • prolactin
  • neuroendocrine system